Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Cash (2020 - 2025)

Historic Change in Cash for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $19.1 million.

  • Tango Therapeutics' Change in Cash rose 110518.33% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 18315.98%. This contributed to the annual value of $2.3 million for FY2024, which is 6087.18% down from last year.
  • Latest data reveals that Tango Therapeutics reported Change in Cash of $19.1 million as of Q3 2025, which was up 110518.33% from -$19.2 million recorded in Q2 2025.
  • Tango Therapeutics' Change in Cash's 5-year high stood at $154.1 million during Q3 2021, with a 5-year trough of -$62.2 million in Q4 2021.
  • Moreover, its 5-year median value for Change in Cash was -$4.3 million (2022), whereas its average is $1.6 million.
  • The largest annual percentage gain for Tango Therapeutics' Change in Cash in the last 5 years was 982586.78% (2021), contrasted with its biggest fall of 5967268.04% (2021).
  • Tango Therapeutics' Change in Cash (Quarter) stood at -$62.2 million in 2021, then skyrocketed by 35.17% to -$40.3 million in 2022, then soared by 119.46% to $7.9 million in 2023, then soared by 108.63% to $16.4 million in 2024, then increased by 16.38% to $19.1 million in 2025.
  • Its Change in Cash stands at $19.1 million for Q3 2025, versus -$19.2 million for Q2 2025 and -$11.1 million for Q1 2025.